Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-OX40/TNFRSF4 Antibody (2E203) is a Mouse antibody targeting OX40/TNFRSF4. Anti-OX40/TNFRSF4 Antibody (2E203) can be used in FCM.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 100 μL | $198 | 7-10 days | 7-10 days |
| Description | Anti-OX40/TNFRSF4 Antibody (2E203) is a Mouse antibody targeting OX40/TNFRSF4. Anti-OX40/TNFRSF4 Antibody (2E203) can be used in FCM. |
| Synonyms | TXGP1L, tumor necrosis factor receptor superfamily, member 4, OX40, IMD16, CD134, ACT35 |
| Ig Type | Mouse IgG1 |
| Clone | 2E203 |
| Reactivity | Human |
| Specificity | Human OX40/TNFRSF4 |
| Verified Activity | Flow cytometric analysis of Human OX40 expression on PHA-activated human whole blood lymphocytes. Cells were stained with purified anti-Human OX40, then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. |
| Application | |
| Recommended Dose | FCM: 1:25-1:100 |
| Antibody Type | Monoclonal |
| Host Species | Mouse |
| Construction | This product is a recombinant monoclonal antibody expressed from HEK293 cells. |
| Purification | Protein A |
| Appearance | Liquid |
| Formulation | 0.2 μm filtered solution in PBS |
| Research Background | OX40 (CD134) and its binding partner, OX40L (CD252), are members of the tumor necrosis factor receptor/tumor necrosis factor superfamily, is known to break an existing state of tolerance in malignancies, leading to a reactivation of antitumor immunity. The interaction between OX40 and OX40L plays an important role in antigen-specific T-cell expansion and survival. OX40 and OX40L also regulate cytokine production from T cells, antigen-presenting cells, natural killer cells, and natural killer T cells, and modulate cytokine receptor signaling. In line with these important modulatory functions, OX40-OX40L interactions have been found to play a central role in the development of multiple inflammatory and autoimmune diseases, making them attractive candidates for intervention in the clinic. Conversely, stimulating OX40 has shown it to be a candidate for therapeutic immunization strategies for cancer and infectious disease.Cancer ImmunotherapyCo-stimulatory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy |
| Conjucates | Unconjugated |
| Others Formats | FITC/PE |
| Antibody Types Available | 3 |
| Immunogen | Recombinant Protein: Human OX40 Protein (TMPY-01423) |
| Antigen Species | Human |
| Biology Area | Cancer Drug Targets |
| Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
| Transport | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.